Ibyerekeye-kanseri / kuvura / ivuriro-ibigeragezo / indwara / kanseri y'uruhu / kuvura
Kuvura Ibigeragezo bivura Kanseri y'uruhu itari Melanoma
Igeragezwa rya Clinical ni ubushakashatsi bwubushakashatsi burimo abantu. Ibizamini byamavuriro kururu rutonde ni ibya kanseri y'uruhu itari melanoma. Ibigeragezo byose kurutonde bishyigikiwe na NCI.
Amakuru yibanze ya NCI kubyerekeye ibizamini byamavuriro asobanura ubwoko nicyiciro cyibigeragezo nuburyo bikorwa. Igeragezwa rya Clinical rireba uburyo bushya bwo kwirinda, gutahura, cyangwa kuvura indwara. Urashobora gushaka gutekereza kubijyanye no kwitabira ikizamini cyamavuriro. Vugana na muganga wawe kugirango agufashe guhitamo niba umwe akubereye.
Ikigeragezo 1-25 cya 118 1 2 3 4 5 Ibikurikira>
Ubuvuzi bugamije kuyobora buyobowe na testi ya genetike mukuvura abarwayi bafite ibibyimba bigezweho bya Lymphoma, Lymphoma, cyangwa Myeloma myinshi (Ikigeragezo CY'IMIKINO)
Iki cyiciro cya II CY'IMIKORESHEREZE yiga uburyo ubuvuzi buyobowe nogupima geneti bukora kubarwayi bafite ibibyimba bikomeye cyangwa lymphoma byateye imbere nyuma yumurongo umwe wubuvuzi busanzwe cyangwa bidafite uburyo bwo kuvura buhari. Ibizamini bya genetike bireba ibintu byihariye (genes) byingirangingo yibibyimba byabarwayi. Abarwayi bafite imiterere idasanzwe (nka mutation, amplification, cyangwa translocations) barashobora kungukirwa cyane nubuvuzi bwibasira ibibyimba byabo bidasanzwe. Kumenya ubwo buryo budasanzwe bwambere bishobora gufasha abaganga gutegura uburyo bwiza bwo kuvura abarwayi bafite ibibyimba bikomeye, lymphoma, cyangwa myeloma myinshi.
Aho uherereye: 1189
Nivolumab nyuma yubuvuzi bukomatanyije bwo kuvura abarwayi bafite ibyago byinshi Icyiciro cya II-IIIB Kanseri ya Anal
Igeragezwa ryicyiciro cya kabiri cyamavuriro yiga uburyo nivolumab nyuma yo kuvura uburyo bwo kuvura ikora muburyo bwo kuvura abarwayi bafite kanseri yo mu cyiciro cya II-IIIB. Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira.
Aho uherereye: 745
Pembrolizumab Ugereranije nubuziranenge bwo Kwita ku Kuvura abarwayi bafite Icyiciro Cyuzuye Cyuzuye I-III Kanseri y'akagari ka Merkel
Iki cyiciro cya III cyigeragezo cyiga uburyo pembrolizumab ikora neza ugereranije nubuziranenge bwo kwita kubuvuzi mu kuvura abarwayi ba kanseri yo mu cyiciro cya I-III Merkel yakuweho burundu no kubagwa (resected). Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira.
Aho uherereye: 286
Avelumab hamwe na Cetuximab cyangwa idafite kuvura abarwayi bafite Kanseri y'uturemangingo twiza cyane
Iki cyiciro cya II cyikigereranyo cyiga uburyo avelumab ifite cyangwa idafite cetuximab ikora mukuvura abarwayi bafite kanseri y'uruhu rwanduye yakwirakwiriye ahandi mu mubiri (yateye imbere). Immunotherapy hamwe na antibodiyite za monoclonal, nka avelumab na cetuximab, birashobora gufasha umubiri wumubiri kwibasira kanseri, kandi birashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira.
Aho uherereye: 277
Pembrolizumab hamwe na Stereotactique Imirasire yumubiri mu kuvura abarwayi bafite kanseri yo mu bwoko bwa Merkel yateye imbere cyangwa Metastatike
Igeragezwa ryicyiciro cya kabiri cyiga uburyo pembrolizumab ifite cyangwa idafite imiti ivura imirasire yumubiri itagira imbaraga ikora mukuvura abarwayi ba kanseri ya selile ya Merkel yakwirakwiriye ahandi mu mubiri. Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira. Imiti ivura imirasire ya stereotactique ikoresha ibikoresho byihariye kugirango ishyire umurwayi kandi itange imirasire yibibyimba neza. Ubu buryo burashobora kwica selile yibibyimba hamwe na dosiye nkeya mugihe gito kandi bigatera kwangirika kwinyama zisanzwe. Gutanga pembrolizumab hamwe nubuvuzi bwimirasire yumubiri bishobora gukora neza mukuvura abarwayi ba kanseri ya selile ya Merkel.
Aho uherereye: 246
Ingaruka n’umutekano Kwiga Tisotumab Vedotine kubarwayi bafite ibibyimba bikomeye
Iki kigeragezo kiziga tisotumab vedotin kugirango hamenyekane niba ari uburyo bwiza bwo kuvura ibibyimba bimwe na bimwe n'ingaruka mbi (ingaruka zitifuzwa) zishobora kubaho. Ubuvuzi buzahabwa abarwayi buri byumweru bitatu.
Aho uherereye: ahantu 12
PD-1 mu barwayi bafite kanseri y'ibanze ya Kanseri Yambere Yiboneye Iterambere ry'indwara kuri Hedgehog Pathway Inhibitor Therapy, cyangwa Ntiyihanganira Ubuvuzi bwa Hedgehog Pathway Inhibitor.
Intego yibanze nugereranya igipimo rusange cyibisubizo (ORR) kuri metasatike Basal Cell Carcinoma (BCC) (itsinda rya 1) hamwe na BCC yateye imbere mu karere (itsinda rya 2) mugihe bavuwe na REGN2810 nkubuvuzi bumwe
Aho uherereye: ahantu 15
Icyiciro cya II Kwiga Tipifarnib mumutwe wa kanseri yumutwe hamwe na kanseri yijosi hamwe na HRAS ihinduka
Icyiciro cya II cyiga gukora iperereza kubikorwa bya antitumor ukurikije igipimo cyo gusubiza ibintu (ORR) ya tipifarnib mu masomo afite ibibyimba byateye imbere bitwara ihinduka rya HRAS kandi kuri bo nta muti usanzwe wo kuvura uhari. Icyitonderwa; Gusa cohort 2 (Umutwe & Ijosi SCC) na cohort 3 (Izindi SCC) zirakinguye
Aho uherereye: ahantu 11
Iperereza ryakozwe na Immuno-therapy Inyigo yo gukora iperereza ku mutekano n’ingirakamaro bya Nivolumab, hamwe nubuvuzi bwa Nivolumab mu kuvura indwara ziterwa na virusi.
Intego yubu bushakashatsi yo gukora iperereza ku mutekano n’ingirakamaro bya nivolumab, hamwe n’ubuvuzi bwa nivolumab, kuvura abarwayi bafite ibibyimba biterwa na virusi. Virusi zimwe zizwiho kugira uruhare mukubyimba no gukura. Ubu bushakashatsi buzasesengura ingaruka z’imiti y’ubushakashatsi, ku barwayi bafite ibibyimba bikurikira: - Kanseri yo mu muyoboro w’amaraso-Ntibikiri kwandikisha ubu bwoko bw’ibibyimba - Kanseri y'inkondo y'umura - Epstein Barr Virus (EBV) kanseri nziza yo mu gifu-Ntibikiyandikisha ibi ubwoko bw'ikibyimba - Kanseri y'akagari ka Merkel - Kanseri y'imboro-Ntibikiri kwiyandikisha muri ubu bwoko bw'ikibyimba - Kanseri yo mu nda ibyara na vulvar-Ntibikiri kwiyandikisha muri ubu bwoko bw'ikibyimba - Kanseri ya Nasopharyngeal - Ntukiyandikisha ubu bwoko bw'ikibyimba - Kanseri yo mu mutwe no mu ijosi - Ntabwo ukiyandikisha ubu bwoko bw'ikibyimba
Aho uherereye: ahantu 10
Pembrolizumab na Placebo Nyuma yo kubagwa no kurasa mubitabiriye hamwe na kanseri yo mu bwoko bwa Cutaneous Squamous Cell Carcinoma (MK-3475-630 / KEYNOTE-630)
Ubu ni ubushakashatsi butemewe, buhumye-buhumye, ubushakashatsi bugereranya pembrolizumab na placebo yatanzwe nk'ubuvuzi bujyanye no kwitabira abitabiriye amahugurwa afite ibyago byinshi byo mu karere ka kanseri yo mu bwoko bwa kanseri (LA cSCC) babazwe bafite intego yo kuvura bifatanije na radiotherapi. Igitekerezo cyibanze ni uko pembrolizumab iruta umwanya wa platbo mukwongera kubaho kubuntu (RFS).
Aho uherereye: ahantu 10
Ubu bushakashatsi busuzuma KRT-232, Inzitizi yo mu kanwa Ntoya ya Molecule Inhibitor ya MDM2, yo kuvura abarwayi bafite (p53WT) Mercel Cell Carcinoma Yananiwe Kurwanya PD-1 / PD-L1 Immunotherapy
Ubu bushakashatsi busuzuma KRT-232, igitabo gishya cya molekile ntoya yo mu kanwa ya MDM2, kugira ngo ivure abarwayi bafite kanseri ya Merkel Cell Carcinoma (MCC) bananiwe kwivuza nibura imwe irwanya PD-1 cyangwa irwanya PD-L1. Kubuza MDM2 nuburyo bushya bwibikorwa muri MCC. Ubu bushakashatsi ni Icyiciro cya 2, Gufungura-Ikirango, Kwiga ukuboko kumwe kwa KRT-232 ku barwayi bafite p53 Ubwoko bw'inyamanswa (p53WT) Merkel Cell Carcinoma
Aho uherereye: ahantu 11
Ubushakashatsi bwa XmAb®23104 mubintu bifite ibyatoranijwe bihanitse bikabije (DUET-3)
Iki nicyiciro cya 1, igipimo cyinshi, ubushakashatsi bwiyongera bwa dose escalation kugirango busobanure MTD / RD nuburyo bwa XmAb23104, gusobanura umutekano no kwihanganirana, gusuzuma PK na immunogenicite, no gusuzuma mbere na mbere ibikorwa byo kurwanya ibibyimba bya XmAb23104 mubisomo byatoranijwe ibibyimba bikomeye.
Aho uherereye: ahantu 9
Adjuvant Avelumab muri Kanseri ya Merkel
Igeragezwa ryicyiciro cya III ryiga uburyo avelumab ikora neza mukuvura abarwayi ba kanseri ya selile ya Merkel yakwirakwiriye mu mitsi kandi bakaba barabazwe cyangwa badafite imiti ivura imirase. Antibodiyite za Monoclonal, nka avelumab, zirashobora gukangura ubudahangarwa bw'umubiri kandi bikabangamira ubushobozi bw'uturemangingo tw'ibibyimba gukura no gukwirakwira.
Aho uherereye: ahantu 10
QUILT-3.055: Inyigo ya ALT-803 ifatanije na PD-1 / PD-L1 Inhibitor ya Inhibitor mu barwayi bafite Kanseri Yateye imbere
Iki nicyiciro cya IIb, ukuboko kumwe, multicohort, gufungura-label multicenter ubushakashatsi bwakozwe na ALT-803 bufatanije na FDA yemewe na PD-1 / PD-L1 inhibitori kubarwayi bafite kanseri yateye imbere bateye imbere nyuma yo kubisubiza bwa mbere kuvura hamwe na PD-1 / PD-L1 igenzura rya inhibitori. Abarwayi bose bazahabwa imiti ivura PD-1 / PD-L1 igenzura hiyongereyeho ALT-803 kugeza kuri 16. Buri cyiciro ni ibyumweru bitandatu. Abarwayi bose bazahabwa ALT-803 rimwe mubyumweru 3. Abarwayi bazahabwa kandi inhibitori ya bariyeri bakiriye mugihe cyo kuvura kwabo. Isuzuma rya radiologique rizabaho nyuma ya buri cyiciro cyo kuvura. Umuti uzakomeza kugeza kumyaka 2, cyangwa kugeza igihe umurwayi yiboneye yemeje indwara igenda itera imbere cyangwa uburozi butemewe, akuraho uruhushya, cyangwa niba Umushakashatsi yumva bitakiri inyungu zumurwayi gukomeza kwivuza. Abarwayi bazakurikiranwa niterambere ryindwara, nyuma yubuvuzi, no kubaho mugihe cyamezi 24 ashize ubuyobozi bwa mbere bwibi biyobyabwenge.
Aho uherereye: ahantu 9
Umutekano, Ubworoherane, Ubudahangarwa, hamwe nigikorwa cya Antitumor ya GEN-009 Urukingo rwahujwe
Muri ubu bushakashatsi, Genocea irimo gusuzuma urukingo rw’iperereza, rwihariye ku giti cye, GEN-009, ruri gukorwa mu rwego rwo kuvura abarwayi bafite ibibyimba bikomeye. Igikoresho cyihariye cyakozwe na Genocea, cyitwa ATLAS ™ (Antigen Lead Acquisition Sisitemu) kizakoreshwa kugirango hamenyekane neoantigens mu kibyimba cya buri murwayi kizwi na CD4 na / cyangwa CD8 T. ATLAS yamenyekanye na neoantigens noneho izashyirwa mu rukingo rwihariye rw’umurwayi mu buryo bwa peptide ndende (SLPs).
Aho uherereye: ahantu 9
Ubushakashatsi bwa NKTR-262 bufatanije na NKTR-214 hamwe na NKTR-214 Plus Nivolumab mu barwayi bafite Indwara mbi cyangwa Metastatike Solid Tumor Malignancies
Abarwayi bazahabwa intra-tumorale (IT) NKTR-262 mugihe cyibyumweru 3 byo kuvura. Mugice cya 1 dose escalation igice cyiburanisha, NKTR-262 izahuzwa nubuyobozi bwa sisitemu ya bempegaldesleukin. Nyuma yo kumenya icyiciro cya 2 gisabwa (RP2D) cya NKTR-262, abarwayi bari hagati ya 6 na 12 barashobora kwiyandikisha kuri RP2D kugirango barusheho kuranga imiterere yumutekano no kwihanganira guhuza NKTR 262 hiyongereyeho bempegaldesleukin (kabiri) cyangwa NKTR 262 wongeyeho bempegaldesleukin ifatanije na nivolumab (inyabutatu) muri Cohorts A na B, kimwe. Mugice cya 2 icyiciro cyo kwagura igice, abarwayi bazavurwa inshuro ebyiri cyangwa eshatu mugice cyisubiramo / cyangiritse hamwe nimirongo yambere yubuvuzi.
Aho uherereye: ahantu 14
Ikigeragezo Cyemewe cya Pembrolizumab & Radiotherapy na Radiotherapy muri Risk-Risk Yoroheje Tissue Sarcoma ya Extremite
Ubu ni label ifunguye, ibyiciro byinshi byicyiciro cya II ubushakashatsi bwateganijwe ugereranije na neoadjuvant radiotherapi ikurikirwa no kubagwa kwa neoadjuvant pembrolizumab hamwe na radiotherapi hamwe, hakurikiraho kubagwa no kubaga pembrolizumab. Igihe cyose cya pembrolizumab kizaba umwaka umwe mumaboko yubushakashatsi.
Aho uherereye: ahantu 10
Imiti ya Proton cyangwa Photon-ishingiye kuri Intensi-Yakozwe na Radiyo yo kuvura abarwayi bafite kanseri ya Glande ya Salivary, Kanseri y'uruhu, cyangwa Melanoma
Igeragezwa ryicyiciro cya II ryiga ku ngaruka ziterwa na proton beam cyangwa foton ishingiye ku mbaraga-modulasi ivura imishwarara yo kuvura abarwayi bafite kanseri ya glande y'amacandwe, kanseri y'uruhu, cyangwa melanoma. Imiti ivura imishwarara ya proton ikoresha uduce duto duto duto kugira ngo itange imirasire mu kibyimba kandi ishobora kwangiza bike ku ngingo zisanzwe. Imiti ihindagurika cyangwa ifotora imishwarara ikoresha imiti ikoresha ingufu za x-ray zifite imbaraga zo kuvura ikibyimba kandi zishobora no kwangiza bike mubice bisanzwe. Kugeza ubu ntiharamenyekana niba imiti ivura imishwarara ya proton ikora neza kuruta kuvura imishwarara ya fotone ishingiye ku kuvura abarwayi ba kanseri y'amacandwe, kanseri y'uruhu, cyangwa melanoma.
Aho uherereye: ahantu 8
Uruhu rwa elegitoronike Ubuso bwa Brachytherapy mukuvura abarwayi bakuze bafite indwara nshya yasuzumwe hakiri kare Basal selile cyangwa kanseri y'uruhu rwa selile.
Igeragezwa ry’amavuriro ryiga uburyo uruhu rwa elegitoroniki rwitwa brachytherapy (ESSB) rukora neza mukuvura abarwayi bakuze barwaye indwara ya kanseri yibanze cyangwa kanseri y'uruhu. ESSB ni ubwoko bwimiti ivura imirasire ikoresha uruhu rusaba uruhu kugirango rushyireho imishwarara ya elegitoronike ivura kanseri yuruhu. Uruhu rusaba uruhu ruzengurutse, disiki yoroshye ifatanye nimashini ivura imirasire, kandi itanga imirasire kugirango ivurwe. ESSB irashobora kwemerera ikibyimba kuvurwa mugihe ibice byubuzima bwiza bitangizwa nimirase.
Aho uherereye: ahantu 8
Ubuvuzi bwa Stereotactique yumubiri mu kuvura abarwayi bafite kanseri ya Metastatike hamwe niterambere rito kuri Inhibitori ya Immune.
Iki cyiciro cya II cyigeragezo cyiga uburyo imiti ivura imirasire yumubiri itera imbaraga mukuvura abarwayi ba kanseri yakwirakwiriye ahandi mu mubiri hamwe niterambere rito mugihe bari kuri bariyeri. Imiti ivura imirasire ya stereotactique ikoresha ibikoresho byihariye kugirango ishyire umurwayi kandi itange imirasire yibibyimba neza. Ubu buryo burashobora kwica selile yibibyimba hamwe na dosiye nkeya mugihe gito kandi bigatera kwangirika kwinyama zisanzwe.
Aho uherereye: ahantu 7
Cabozantinib S-malate na Cetuximab mu kuvura abarwayi bafite umutwe wa Metastatike hamwe na kanseri y'utugari twizosi.
Iki cyiciro cya I kigeragezo cyiga ku ngaruka n'ingaruka nziza za cabozantinib S-malate kandi iyo itanzwe hamwe na cetuximab mu kuvura abarwayi bafite kanseri y'uturemangingo yo mu mutwe no mu ijosi yakwirakwiriye ahandi mu mubiri. Cabozantinib S-malate irashobora gutinda gukura kwingirangingo za kanseri muguhagarika amaraso kanseri ikeneye kubaho no gukura. Immunotherapy hamwe na antibodiyite za monoclonal, nka cetuximab, irashobora gutera impinduka mumubiri wumubiri kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zo gukura no gukwirakwira. Gutanga cabozantinib S-malate na cetuximab birashobora gukora neza mukuvura abarwayi ba kanseri yo mumutwe no mumajosi.
Aho uherereye: ahantu 7
Umutekano, Ingaruka Yibanze na PK ya Isatuximab (SAR650984) Wenyine cyangwa muguhuza na Atezolizumab mubarwayi bafite indwara mbi mbi
Intego z'ibanze: - Icyiciro1: Kuranga umutekano no kwihanganira isatuximab ifatanije na atezolizumab mubitabiriye hamwe na kanseri ya hepatocellular idashobora gukira (HCC), platine-retractory isubiramo / metastatike squamous selile kanseri yumutwe nijosi (SCCHN), irwanya platine / irwanya platine kanseri ya epithelial ovarian kanseri (EOC), cyangwa glioblastoma multiforme isubirwamo (GBM), no kumenya icyiciro cya 2 gisabwa (RP2D). - Icyiciro2: Gusuzuma igipimo cyibisubizo (RR) cya isatuximab ifatanije na atezolizumab mubitabiriye hamwe na HCC cyangwa SCCHN cyangwa EOC. - Icyiciro2: Gusuzuma iterambere ryokubaho kubuntu mumezi 6 (PFS-6) ya isatuximab ifatanije na atezolizumab, cyangwa nkumukozi umwe mubitabiriye GBM. Intego za kabiri: - Gusuzuma umwirondoro wumutekano wa isatuximab monotherapy (GBM gusa), cyangwa ufatanije na atezolizumab mu cyiciro cya 2. - Gusuzuma ubudahangarwa bwa isatuximab na atezolizumab. - Kuranga imiterere ya farumasi (PK) yumwirondoro wa isatuximab umwe (GBM gusa) na atezolizumab ifatanije na isatuximab. - Gusuzuma imikorere rusange ya isatuximab ifatanije na atezolizumab, cyangwa umukozi umwe (GBM gusa).
Aho uherereye: ahantu 7
Ubushakashatsi bwa INCMGA00012 muri Metastatike Merkel Cell Carcinoma (POD1UM-201)
Intego yubu bushakashatsi ni ugusuzuma ibikorwa byubuvuzi n’umutekano bya INCMGA00012 mubitabiriye hamwe na kanseri ya selile ya Merkel yateye imbere (MCC).
Aho uherereye: ahantu 8
Lenvatinib Mesylate na Cetuximab mu kuvura abarwayi bafite umutwe wongeye kugaruka cyangwa Metastatike hamwe na Nec squamous Cell Carcinoma cyangwa Cutaneous Squamous Cell Carcinoma
Iki cyiciro cya I / Ib cyiga ikigereranyo cyiza ningaruka mbi za lenvatinib mesylate na cetuximab mukuvura abarwayi bafite kanseri yo mu mutwe no mu ijosi kanseri ya kanseri cyangwa kanseri ya selile kanseri yagarutse (isubiramo) cyangwa ikwirakwira ahandi mu mubiri (metastatike ). Lenvatinib mesylate irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure. Antibodiyite za Monoclonal, nka cetuximab, zishobora kubangamira ubushobozi bwingirabuzimafatizo zo gukura no gukwirakwira. Gutanga lenvatinib mesylate na cetuximab birashobora gukora neza mukuvura abarwayi bafite kanseri yo mu mutwe no mu ijosi kanseri ya kanseri cyangwa kanseri yo mu bwoko bwa kanseri.
Aho uherereye: ahantu 7
PEN-221 muri reseptor ya Somatostatin 2 Kugaragaza Kanseri Yateye imbere Harimo Neuroendocrine na Kanseri Ntoya ya Kanseri y'ibihaha Porotokole PEN-221-001 ni ikirango gifunguye, icyiciro cya 1 / 2a ubushakashatsi busuzuma PEN-221 ku barwayi bafite SSTR2 bagaragaza gastroenteropancreatic (GEP) cyangwa ibihaha cyangwa thymus cyangwa ibindi bibyimba bya neuroendocrine cyangwa kanseri y'ibihaha ntoya cyangwa kanseri nini ya neuroendocrine kanseri y'ibihaha.
Aho uherereye: ahantu 7
1 2 3 4 5 Ibikurikira> Ikigo cyigihugu cya kanseri
